Core One Labs (COOL.C) subsidiary Vocan Biotechnologies finished putting together the required equipment to start artificially producing psilocybin today, according to a press release.

Acquired in December, Vocan has now received and assembled the required equipment to go forward with their plans to produce biosynthesized psilocybin. The company considers this a critical milestone in their development plan because of the cost and long lead times associated with the acquisition. Now Vocan is able to improve their present lab work and are actually ahead of schedule on its plans for beginning the rocombinant production of psilocybin.

“Vocan’s recombinant production of psilocybin is a significant improvement over the current methods of psilocybin production. Reducing both the cost and time needed to produce and purify psilocybin to only a few days, compared to much longer and more expensive methods for whole mushroom extraction. Having the equipment purchased and assembled positions Vocan to execute on its objectives in the short term,” said Joel Shacker, Core One’s CEO.

Core One is a biotech research and development company involved in life sciences and more specifically in the developing psychedelic space. They’re developing novel delivery systems to be used in psychedelic assisted psychotherapy. They have a patent pending thin film oral strip, which dissolves inside the mouth and delivers the desired chemical directly to the bloodstream. The company intends on furthering its technology intellectual property by focusing on psychedelic delivery, with their first target being psilocybin.

Vocan’s platform can duplicate naturally occurring compounds in a lab using a gene mimicry process and simple chemical modifications. The process involves engineering bacteria using optimized biosynthetic genes from the Psilocybe cubensis mushrooms, which enables the bacteria to act as a biological factory in order to artificially develop psilocybin.

Source: stockwatch.com

Core One Labs seems to have taken the adage new year new you to heart. They recently only came back online after shedding their old skin (they were once Lifestyle Delivery Systems) and bouncing back with a new gameplan, new blood and new vigor.  When they returned midway through November they were barely a $0.30 play and a shaky one at that as they had yet to prove themselves to both new and long-time investors.  But now it would seem that COOL’s near triple has finally rewarded those who wait and keep the faith.

—Joseph Morton

Full disclosure: Core One Labs is an equity.guru marketing client.

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Tags:
Shroom Boom
biosynthetic compounds
COOL.C
Core One Labs
Lifestyle Delivery Systems
magic mushrooms
magic mushrooms market
psilocybe cubensis mushrooms
psilocybe mushrooms
Psilocybin
synthetic psilocybin
Vocan
Vocan Biotechnologies
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments